Oncorus Inc. (ONCR) News
Filter ONCR News Items
ONCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ONCR News Highlights
- For ONCR, its 30 day story count is now at 4.
- Over the past 14 days, the trend for ONCR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ONCR are LI, RNA and UL.
Latest ONCR News From Around the Web
Below are the latest news stories about ONCORUS INC that investors may wish to consider to help them evaluate ONCR as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as investors get ready to trade shares on Wednesday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! |
Why Is Cyxtera Technologies (CYXT) Stock Down 19% Today?Cyxtera Technologies (CYXT) stock is falling Monday as the company continues with its bankruptcy filing and heavy trading pulls shares down. |
Why Is Oncorus (ONCR) Stock Down 27% Today?Oncorus (ONCR) stock is taking a beating on Monday after revealing plans for a vote during an upcoming special shareholder meeting. |
Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy ThreatOncorus (ONCR) decides to lay off nearly all of its workforce since it is facing challenges in raising additional capital. This lay off is expected to be completed by August 2023. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time for a dive into the biggest pre-market stock movers for Friday as we check out the winners and losers this morning! |
Oncorus Announces Workforce Reduction PlanANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company’s board of directors has approved a workforce reduction of approximately 55 |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for a look at the biggest pre-market stock movers on Tuesday morning with all the details traders need to know about! |
Oncorus GAAP EPS of -$1.18 misses by $0.48
|
Oncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesIND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneeri |